{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BriaCell Therapeutics Corp."},"Symbol":{"label":"Symbol","value":"BCTXW"},"Address":{"label":"Address","value":"235 - 15TH STREET,SUITE 300, WEST VANCOUVER, VANCOUVER, British Columbia, V7T 2X1, Canada"},"Phone":{"label":"Phone","value":"+1 604 921-1810"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers."},"CompanyUrl":{"label":"Company Url","value":"https://www.briacell.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Guiseppe Del Priore","title":"Chief Medical Officer"},{"name":"Miguel A. Lopez-Lago","title":"Chief Scientific Officer"},{"name":"William V. Williams","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}